Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RPRX 
Royalty Pharma Plc (RPRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: RPRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $44.5
1 Year Target Price $44.5
| 4 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.99% | Avg. Invested days 44 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 21.48B USD | Price to earnings Ratio 16.09 | 1Y Target Price 44.5 |
Price to earnings Ratio 16.09 | 1Y Target Price 44.5 | ||
Volume (30-day avg) 8 | Beta 0.59 | 52 Weeks Range 23.59 - 37.97 | Updated Date 10/23/2025 |
52 Weeks Range 23.59 - 37.97 | Updated Date 10/23/2025 | ||
Dividends yield (FY) 2.29% | Basic EPS (TTM) 2.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 44.28% | Operating Margin (TTM) 38.85% |
Management Effectiveness
Return on Assets (TTM) 6.49% | Return on Equity (TTM) 17.29% |
Valuation
Trailing PE 16.09 | Forward PE 10.59 | Enterprise Value 22288826394 | Price to Sales(TTM) 9.32 |
Enterprise Value 22288826394 | Price to Sales(TTM) 9.32 | ||
Enterprise Value to Revenue 9.67 | Enterprise Value to EBITDA 11.53 | Shares Outstanding 432293050 | Shares Floating 379847257 |
Shares Outstanding 432293050 | Shares Floating 379847257 | ||
Percent Insiders 8.73 | Percent Institutions 82.97 |
Upturn AI SWOT
Royalty Pharma Plc
Company Overview
History and Background
Royalty Pharma was founded in 1996. It is a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It has grown to become a leading player in the royalty acquisition space.
Core Business Areas
- Acquisition of Royalties: Acquires royalties on approved and marketed biopharmaceutical products, as well as late-stage development candidates.
- Funding Innovation: Provides funding to biopharmaceutical companies to support research and development in exchange for future royalties.
Leadership and Structure
The CEO is Pablo Legorreta. The organizational structure includes departments focused on investments, finance, legal, and investor relations.
Top Products and Market Share
Key Offerings
- Tysabri: Royalty Pharma holds royalties on Tysabri, a multiple sclerosis treatment. Competitors include therapies from Biogen and Novartis. Revenue not available.
- Januvia/Janumet: Royalty Pharma holds royalties on Januvia/Janumet, used to treat type 2 diabetes. Competitors include other diabetes medications from Novo Nordisk and Eli Lilly. Revenue not available.
- Emgality: Royalty Pharma holds royalties on Emgality, a migraine treatment. Competitors include other CGRP inhibitors from Amgen and AbbVie. Revenue not available.
- Tremfya: Royalty Pharma holds royalties on Tremfya, a plaque psoriasis treatment. Competitors include other psoriasis medications from AbbVie and Novartis. Revenue not available.
Market Dynamics
Industry Overview
The pharmaceutical royalty market is a niche within the broader pharmaceutical industry, characterized by high barriers to entry and specialized expertise.
Positioning
Royalty Pharma is a leading player in acquiring pharmaceutical royalties, giving it a strong position due to its large capital base and experienced team.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be over $1 trillion. Royalty Pharma targets royalties on a portion of these sales, positioning it in a multi-billion dollar TAM.
Upturn SWOT Analysis
Strengths
- Large capital base
- Experienced management team
- Diversified royalty portfolio
- Established relationships with biopharmaceutical companies
Weaknesses
- Dependence on the success of underlying drugs
- High capital intensity
- Vulnerability to generic competition for royalty-generating drugs
Opportunities
- Increasing R&D spending in the biopharmaceutical industry
- Growing number of approved drugs
- Expansion into new therapeutic areas
- Potential acquisitions of royalty portfolios
Threats
- Patent expirations of royalty-generating drugs
- Regulatory changes affecting drug pricing
- Competition from other royalty buyers
- Failure of clinical trials for development-stage drugs
Competitors and Market Share
Key Competitors
- DRI Healthcare Trust (DHT.UN.TO)
- Healthcare Royalty Partners
- OMERS Capital Markets
Competitive Landscape
Royalty Pharma has a strong competitive advantage due to its scale and experience. Competitors are smaller and may have different investment strategies.
Major Acquisitions
Azafaros B.V.
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: Royalty Pharma will acquire a royalty on sales of AZ-3102 following potential FDA approval.
Growth Trajectory and Initiatives
Historical Growth: Requires actual financial data to populate accurately.
Future Projections: Requires analyst estimates to populate accurately.
Recent Initiatives: Focus on acquiring royalties on innovative therapies and expanding into new therapeutic areas.
Summary
Royalty Pharma is a unique player in the pharmaceutical industry with a strong position in royalty acquisitions. Its strengths include a large capital base and diverse portfolio; however, its dependence on underlying drug success and patent expirations pose risks. Expanding into new therapeutic areas and making strategic acquisitions will be key to maintaining future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Royalty Pharma Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Royalty Pharma Plc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 1993-03-25 | Founder, Chairman of the Board & CEO Mr. Pablo Gerardo Legorreta | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.royaltypharma.com |
Full time employees - | Website https://www.royaltypharma.com | ||
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.